Generation of iPSC lines from archived non-cryoprotected biobanked dura mater
- Andrew A Sproul†1,
- Lauren B Vensand†1,
- Carmen R Dusenberry1,
- Samson Jacob1,
- Jean Paul G Vonsattel2,
- Daniel J Paull1,
- Michael L Shelanski2,
- John F Crary2Email author and
- Scott A Noggle1Email author
© Sproul et al.; licensee BioMed Central Ltd. 2014
Received: 7 November 2013
Accepted: 15 December 2013
Published: 7 January 2014
Induced pluripotent stem cells (iPSCs) derived from patients with neurodegenerative disease generally lack neuropathological confirmation, the gold standard for disease classification and grading of severity. The use of tissue with a definitive neuropathological diagnosis would be an ideal source for iPSCs. The challenge to this approach is that the majority of biobanked brain tissue was not meant for growing live cells, and thus was not frozen in the presence of cryoprotectants such as DMSO.
We report the generation of iPSCs from frozen non-cryoprotected dural tissue stored at −80°C for up to 11 years. This autopsy cohort included subjects with Alzheimer’s disease and four other neurodegenerative diseases.
Disease-specific iPSCs can be generated from readily available, archival biobanked tissue. This allows for rapid expansion of generating iPSCs with confirmed pathology as well as allowing access to rare patient variants that have been banked.
Human iPSC-derived neural cells are attractive models for Alzheimer’s disease and other neurodegenerative diseases because they can be used for cellular investigation of mechanisms and drug screening in vitro. While, to date, most human iPSC models have been derived from rare monogenetic familial forms of neurodegenerative disease, most patients have sporadic disease forms for which post-mortem neuropathological examination is essential for definitive diagnosis. In some cases, tissue from patients with similar symptoms may exhibit quite different pathology. For instance, vascular dementia or frontotemporal lobar degeneration, which can clinically present as AD, may not be correctly diagnosed until post mortem examination of the brain. If tissue from deceased patients that had undergone neuropathological evaluation could be used to generate iPSCs, knowledge of the definitive diagnosis as well as potential stratification of sporadic patients could guide the selection and subsequent use of the cell lines to be made. While generation of iPSCs from fresh autopsy tissue has recently been reported [1, 2], brain bank networks, which contain tens of thousands of samples, could provide a much larger, and more immediate, source of tissue. As these biobanked tissues have not been specifically processed for the derivation of living cells, we have investigated whether it is possible to use them to isolate somatic cells and subsequently reprogram these into iPSCs. This would allow access to large numbers of neuropathologically defined cases, including patients with rare diseases whose frequency is low in clinical populations.
All media components were obtained from Life Technologies unless otherwise indicated. Dural/scalp outgrowths, established fibroblast lines, and mouse embryonic fibroblasts (MEFs, GlobalStem) were grown in fibroblast media, defined as the following: DMEM/10% FBS/Glutamax (2 mM)/2-Mercaptoethanol (0.1 mM)/Penicillin-streptomycin (100 U/mL-0.1 mg/mL). For initial plating of new dural and scalp samples, the tissue was first grown in biopsy media: DMEM/10% FBS/Glutamax (2 mM)/2-Mercaptoethanol (0.1 mM)/MEM non-essential amino acids (0.1 mM)/antibiotic-antimycotic (1×)/Nucleosides (1×, Millipore). Reprogrammed iPSCs were maintained on MEFs, in HUESM: KO-DMEM/20% KSR/Glutamax (2 mM)/2-Mercaptoethanol (0.1 mM)/bFGF (10 ng/ml)/Penicillin-streptomycin (100 U/mL-0.1 mg/mL). iPSCs were enzymatically passaged using TrypLE and replated in the presence of a Rho-kinase inhibitor (Y27632, Stemgent). Karyotyping and DNA fingerprinting of fibroblasts and iPSCs was performed by Cell Line Genetics (Madison, Wisconsin). Directed and undirected differentiations are described below.
Generation of postmortem tissue outgrowths
De-identified donated postmortem brain tissue was obtained through the New York Brain Bank at Columbia University. Neuropathological examination was per standardized protocols [3, 4]. For the pilot study, scalp and dural tissue from the same patient was frozen at the time of autopsy in the presence of 10% DMSO/45% FBS/45% fibroblast media. Subsequent experiments utilized standard banked material that was frozen via a liquid nitrogen vapor sandwich method [3, 4]. Dural tissue was stored as rolled tissue (approximately 1 cm by 5 cm in 2 ml cryovials that have been stored at −80 degrees for 1–11 years. Samples were either thawed entirely for 1 min at 37°C for processing or quickly removed from the vial with forceps while still frozen and a small piece was cut off using a scalpel, to preserve unthawed tissue for future use. Samples were washed twice with PBS and DMEM, then cut into smaller pieces, approximately 2–3 mm by 2–3 mm. One drop of sterile silicon grease was placed in the center of each well of a 6-well cell culture plate and four or five pieces of the tissue were placed around each drop. A coverslip was placed on top of the silicon/samples and 2 ml of biopsy culture media were added to each well. Samples were left undisturbed for five days and then checked for fibroblast outgrowth. Media was switched to fibroblast culture medium and changed every other day. Outgrowth was monitored and fibroblasts were passaged with TrypLE to a new 6-well culture dish when the coverslip and/or plate became at least 50% confluent. Fibroblast cultures were expanded and passaged until sufficient numbers were generated for reprogramming and cryogenic preservation.
Reprogramming using Sendai virus
Fibroblasts between passages 3 and 5 were plated into a 12-well cell culture plate format at 50,000 cells per well in fibroblast culture medium. CytoTune-iPS kits (Life Technologies) containing four Sendai virus vectors (Oct3/4, Sox2, Klf4, c-Myc) were used to infect fibroblasts at an MOI = 3 (transduction volume based on the specific titer of each lot), in fibroblast media. The day after infection, an additional 1 mL of fibroblast media was added to the culture. The next day, the media was switched to HUESM and depending on the severity of Sendai toxicity, MEFs were overlaid on some of the cultures. The medium was changed every day until colonies appeared. Colonies were manually picked and expanded on MEFs.
Dural and scalp fibroblast gene expression profile
RNA was prepared using the RNeasy mini kit (Qiagen) per the manufacturers instructions. cRNA was amplified using the Illumina TotalPrep RNA Amplification Kit (Ambion) and run on an Illumina HT_12_v4 BeadChip Array (Ilumina), as per the manufacturer’s instructions. Analysis of microarray data was performed using Genome Studio software (Illumina).
Immunostaining for pluripotency markers and alkaline phosphatase assay
For pluripotency staining, cultures were fixed using 4% paraformaldehyde (PFA, Santa Cruz) for 12 min at room temperature. After multiple PBS washes the cells were treated with PBS containing 0.1% Triton X-100 (Sigma) and 10% normal donkey serum (Jackson Immuno Research) for 1 hr. Cells were then treated with primary antibodies including Tra-160 (1:200, Millipore), SSEA-4 (1:500, Abcam), Tra-181 (1:200, Millipore), OCT-4 (1:500, Stemgent), Nanog (1:100, Cell Signaling), and SOX-2 (1:500, Stemgent). Alexa-conjugated anti-mouse or anti-rabbit IgG secondary antibodies were used (Invitrogen). AP staining was performed with the Vector Red Alkaline Phosphatase Substrate Kit (Vector Laboratories) per the manufacturers instructions. Nuclei were counterstained with Hoechst 33342 (Sigma).
Nanostring nCounter assay
Total RNA was isolated from each iPSC line using the RNeasy kit (Qiagen) as per the manufacturers instructions. 100 ng of RNA for each sample was analyzed with the NanoString nCounter system (NanoString, Seattle, WA) using a pre-designed codeset. The codeset contains 25 probes for detection of retroviral and Sendai viral transgenes, pluripotency, spontaneous differentiation markers, and housekeeping genes . Data was normalized to the geometric mean using nSolver Analysis Software v1.0 (NanoString) and compared with previous runs of a Sendai-positive control line, a fibroblast line (1043), and two human ESC lines (HUES42 and HUES16).
In vitro pluripotency assay
Undirected embryoid bodies (EB) were formed by placing 10,000 iPSCs in multiple wells of a 96-well non-tissue culture treated V-bottom plate (Evergreen) containing HUESM plus 10 μM ROCKi (Stemgent), and underwent brief centrifugation. After 14 d of culturing EBs were transferred into a 6 well low attachment plates (Corning) and cultured for an additional 16 days. Once harvested EBs were fixed in 4% paraformaldehyde for 20 min at room temperature and processed in 15% and 30% sucrose solutions for one day each at 4°C. EBs were then embedded in O.C.T. (Sakura Finetek) and cryosectioned. The sections were blocked in PBS containing 0.1% Triton X-100 and 10% donkey serum for 1 hr at room temperature, followed by an overnight incubation at 4°C with antibodies identifying the 3 germ layers: SMA (1:500, DAKO), AFP (1:500, DAKO) TuJ1 (1:500, Covance), Sox17 (1:500, R&D Systems). Alexa-conjugated anti-mouse or anti-rabbit IgG secondary antibodies were used (Invitrogen) along with Hoechst 33342 counterstain. Sections were set with Vectashield Hard Set Mounting Media (Vector Laboratories).
Two confluent wells of iPSC line ASC-7D-AD (p.25) were chemically disassociated using dispase (Gibco) and centrifuged for 4 minutes at 800 rpm. For each well, cells were resuspended as clumps in 100 μL of HUESM and added to 100 μl of Matrigel (BD Biosciences) on ice. A three-month-old NSG immune-compromised mouse (Jackson Laboratory) was anaesthetized with isofluorane and injected subcutaneously with a cell-suspension on each dorsal flank, and was sacrificed 75 d post injection. The teratoma was manually extracted, fixed in 4% PFA overnight and embedded in paraffin. Sections were stained with hematoxylin and eosin and histologically examined for developmental germ layers.
Directed neuronal differentiation
MEFs were manually removed and iPSCs were brought to single cells suspension using Accutase (Life Technologies) and plated into a 48-well plate coated with polyornithine (100 μg/mL, Sigma Aldrich)/laminin (3 μg/mL, Invitrogen) at 25,000 cells per well, in mTeSR1 (Stem Cell Technologies) and 10 μM ROCKi. Cells were allowed to recover for 2 days before being switched to custom mTeSR1 (missing five growth factors, Stem Cell Technologies) containing 10 μM SB421542 (Stemgent) and 250 nM LDN193189 (Stemgent). Media was changed completely every 2 days. At Day 11, media was gradually switched with half feeds for the first two changes to neuronal differentiation medium (Neurobasal/B27 without retinoic acid/Glutamax (2 mM)/Penicillin-streptomycin (100 U/mL-0.1 mg/mL).
At days 14 and 21, wells were washed with PBS and fixed using 4% PFA for 12 min at room temperature. After three PBS washes, cells were blocked with 0.1% Triton X-100 and 10% normal donkey serum for 1 hr. Cells were treated with primary antibodies including PAX6 (1:300, Covance), Tuj1 (1:500, Covance), and Sox1 (1:400, Stemgent). Alexa-conjugated anti-mouse or anti-rabbit IgG secondary antibodies were utilized (Invitrogen).
Next, we attempted to reprogram skin and dural lines into a pluripotent state using a Sendai virus integration-free method . After viral infection, both ASC2S-MSA and ASC2D-MSA lines produced colonies with iPS-like morphology. Individual clones were manually picked, expanded, and characterized for stem cell properties such as pluripotency (Figure 1F-H, J-R). ASC2S-MSA-CP and ASC2D-MSA-CP iPSCs (cryoprotected) also displayed a normal female karyotype and fingerprinting confirmed that both lines were derived from the same subject (Additional file 1 and data not shown). These results indicate that both scalp and dural cells can be reprogrammed to produce high-quality iPSCs.
Successful dural outgrowths and iPSC generation
These results demonstrate the potential to leverage existing biorepositories to support research in a powerful new way. While tissue banks in various forms have existed for over 60 years, demand for human tissue for personalized medicine and associated genetic studies, which require large biorepositories, has accelerated the rate of establishment of new facilities [11, 12]. A recent survey has identified at least 636 U.S. biobanks, 36% of which have postmortem tissue, 9% exclusively (largely brain banks) . Archival specimens that were not intended for iPSC generation at the time of harvesting have the potential to be unlocked for functional studies to test mechanistic hypotheses. Preliminary results suggest other banked brain tissues, including leptomeninges and the large artery associated with the choroid plexus, can also produce outgrowths both morphologically similar and distinct from fibroblasts (data not shown). In addition, while many collections store solid tissues, there are other specimens within these banks that might be suitable for generating stem cell lines in the future, including blood, saliva or buccal cells, cord blood and pathological body fluids (e.g, ascites), among others . The majority of biobanks focus on a single disease group, with neoplasia, neurodegeneration and HIV/AIDS being the most common, but there is a rich diversity of diseases represented in these collections that include both common and rare diseases, many of which currently have no cellular models. In the case of Alzheimer’s disease, the Alzheimer’s Disease Education and Referral Center (ADEAR) currently lists 27 NIA funded Alzheimer’s disease centers, each containing a neuropathology core that routinely banks frozen tissue (http://www.nia.nih.gov/research/dn/alzheimers-disease-centers-adcs). While the total number of specimens available for generating iPSCs is difficult to estimate, the National Alzheimer’s Coordinating Center (NACC) has autopsy data from ~13,279 subjects from these centers as of June 1st, 2013 (https://www.alz.washington.edu/WEB/data-descript.html), the majority of which have frozen tissue available.
There is a vital need for well-characterized patient material for translational research . Deriving iPSCs from tissue from patients with neurodegenerative diseases with post-mortem confirmation, which remains the gold standard, is highly advantageous over utilization of lines from patients with clinical ascertainment alone in that there is certainty in the diagnosis. This approach has the additional benefit of having post-mortem brain tissue available for rapid correlation and cross validation of neuropathological and cellular findings.
AS conceived and performed experiments, analyzed data, oversaw research, and drafted/collated the final manuscript. LV conceived and performed experiments, analyzed data, and helped draft and edit the manuscript. CD and DP performed experiments and contributed to experimental design, analyzed data, and helped draft and edit the manuscript. SJ performed teratoma experiments and contributed to experimental design, and prepared data panels for publication. JV provided pathological images, provided samples via the NYBB, and helped edit the manuscript. MS provided intellectual input into the manuscript, helped edit the manuscript, and provided funding. JC conceived the experimental approach, coordinated the cryoprotected pilot, provided pathological images and helped draft and edit the manuscript. SN provided intellectual input into the manuscript, oversaw research, helped edit the manuscript, and provided funding. All authors read and approved the final manuscript.
We would like to thank Zach Hall for a careful reading and helpful feedback on this manuscript. We also thank Etty Cortés for neuropathology support. We express our deepest gratitude to the patients and staff of the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain (P50AG08702/RO1AG037212). This project was funded in part by The American Recovery and Reinvestment Act (ARRA) funds through Grant number P30AG036453 (MLS), the Alzheimer’s Association (NIRG-11-204450), and the Louis V. Gerstner, Jr., Foundation (JFC), and NIH/NIA grant number 1RF1AG042965-02 (SAN). SAN is also generously supported by the Cure Alzheimer’s Fund, Charles Evans Foundation and the New York Stem Cell Foundation.
- Bliss LA, Sams MR, Deep-Soboslay A, et al.: Use of postmortem human dura mater and scalp for deriving human fibroblast cultures. PLoS ONE 2012, 7: e45282. doi:10.1371/journal.pone.0045282 10.1371/journal.pone.0045282View ArticlePubMedPubMed CentralGoogle Scholar
- Hjelm BE, Rosenberg JB, Szelinger S, et al.: Induction of pluripotent stem cells from autopsy donor-derived somatic cells. Neurosci Lett 2011, 502: 219–224. doi:10.1016/j.neulet.2011.07.048 10.1016/j.neulet.2011.07.048View ArticlePubMedPubMed CentralGoogle Scholar
- Vonsattel J-PG, Amaya MDP, Cortes EP, et al.: Twenty-first century brain banking: practical prerequisites and lessons from the past: the experience of New York Brain Bank, Taub Institute, Columbia University. Cell Tissue Bank 2008, 9: 247–258. doi:10.1007/s10561–008–9079-y 10.1007/s10561-008-9079-yView ArticlePubMedPubMed CentralGoogle Scholar
- Vonsattel J-PG, Del Amaya MP, Keller CE: Twenty-first century brain banking: processing brains for research: the Columbia University methods. Acta Neuropathol 2008, 115: 509–532. doi:10.1007/s00401–007–0311–9 10.1007/s00401-007-0311-9View ArticlePubMedGoogle Scholar
- Kahler DJ, Ahmad FS, Ritz A, et al.: Improved methods for reprogramming human dermal fibroblasts using fluorescence activated cell sorting. PLoS ONE 2013, 8: e59867. doi:10.1371/journal.pone.0059867 10.1371/journal.pone.0059867View ArticlePubMedPubMed CentralGoogle Scholar
- Ahmed Z, Asi YT, Sailer A, et al.: The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 2012, 38: 4–24. doi:10.1111/j.1365–2990.2011.01234.x 10.1111/j.1365-2990.2011.01234.xView ArticlePubMedGoogle Scholar
- Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006, 6: 392–401. doi:10.1038/nrc1877 10.1038/nrc1877View ArticlePubMedGoogle Scholar
- Ban H, Nishishita N, Fusaki N, et al.: Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci USA 2011, 108: 14234–14239. doi:10.1073/pnas.1103509108 10.1073/pnas.1103509108View ArticlePubMedPubMed CentralGoogle Scholar
- Mirra SS, Heyman A, McKeel D, et al.: The Consortium to Establish a Registry for Alzheimer“s Disease (CERAD): Part II: standardization of the neuropathologic assessment of Alzheimer”s disease. Neurology 1991, 41: 479–486. 10.1212/WNL.41.4.479View ArticlePubMedGoogle Scholar
- Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82: 239–259. 10.1007/BF00308809View ArticlePubMedGoogle Scholar
- Henderson GE, Cadigan RJ, Edwards TP: Genome medicine. 2013, 5(1):3.Google Scholar
- Hewitt RE: Biobanking: the foundation of personalized medicine. Curr Opin Oncol 2011, 23: 112–119. doi:10.1097/CCO.0b013e32834161b8 10.1097/CCO.0b013e32834161b8View ArticlePubMedGoogle Scholar
- Founti P, Topouzis F, van Koolwijk L, et al.: Biobanks and the importance of detailed phenotyping: a case study–the European Glaucoma Society GlaucoGENE project. Br J Ophthalmol 2009, 93: 577–581. doi:10.1136/bjo.2008.156273 10.1136/bjo.2008.156273View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.